Skip Nav Destination
![]()
You do not currently have access to this content.
A More Selective FGFR Inhibitor for Bladder Cancer
November 6, 2024
A new targeted therapy aimed specifically at FGFR3, TYRA-300, is showing preliminary promise in patients with advanced FGFR3-altered bladder cancer. Partial responses have been seen in an ongoing phase I trial, and the drug is much better tolerated than erdafitinib, a pan–FGFR inhibitor and an approved second-line therapeutic option.
RSS Feeds